In terms of treatment, previous meta-analytical studies have shown a positive impact of immunological treatment by demonstrating the effectiveness of tocilizumab, a humanized monoclonal antibody clinically used as an immunosuppressive agent targeting the interleukin-6 receptor, for reducing the expressions of biomarkers48 and mortality rate49 in patients with COVID-19, underscoring the therapeutic potential of combining anti-cytokine and anticoagulant in patients with moderate to severe COVID-19 infections. This evidence concerns the gene IL6R and COVID-19.